Kraj: Stany Zjednoczone
Język: angielski
Źródło: NLM (National Library of Medicine)
TADALAFIL (UNII: 742SXX0ICT) (TADALAFIL - UNII:742SXX0ICT)
Bryant Ranch Prepack
ORAL
PRESCRIPTION DRUG
Tadalafil tablets, USP are indicated for the treatment of erectile dysfunction (ED). Tadalafil tablets, USP are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tadalafil tablets, USP are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH). If tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see Clinical Studies (14.3)] . Administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. In clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see Clinical Pharmacology (12.2)] . Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets or ADCIRCA® ). Hypersensiti
16.1 How Supplied Tadalafil Tablets, USP are supplied as follows: 2.5 mg: Light yellow to yellow colored, oval-shaped, film-coated tablets, debossed with “T21/2” on one side and plain on other side. NDC: 71335-1823-1: 90 TABLETs in a BOTTLE NDC: 71335-1823-2: 30 TABLETs in a BOTTLE NDC: 71335-1823-4: 20 TABLETs in a BOTTLE NDC: 71335-1823-3: 10 TABLETs in a BOTTLE 16.2 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Keep out of reach of children. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Abbreviated New Drug Application
TADALAFIL- TADALAFIL TABLET BRYANT RANCH PREPACK ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TADALAFIL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TADALAFIL TABLETS. TADALAFIL TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2003 RECENT MAJOR CHANGES Warning and Precautions (5.4) 05/2017 INDICATIONS AND USAGE Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) (1.1) the signs and symptoms of benign prostatic hyperplasia (BPH) (1.2) ED and the signs and symptoms of BPH (ED/BPH) (1.3) If tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks (1.4). DOSAGE AND ADMINISTRATION _Tadalafil tablets for use as needed:_ ED: Starting dose: 10 mg as needed prior to sexual activity. Increase to 20 mg or decrease to 5 mg based upon efficacy/tolerability. Improves erectile function compared to placebo up to 36 hours post dose. Not to be taken more than once per day (2.1). _Tadalafil tablets for once daily use:_ ED: 2.5 mg taken once daily, without regard to timing of sexual activity. May increase to 5 mg based upon efficacy and tolerability (2.2). BPH: 5 mg, taken at approximately the same time every day (2.3) ED and BPH: 5 mg, taken at approximately the same time every day (2.3, 2.4) Tadalafil tablets may be taken without regard to food (2.5). DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg (3). CONTRAINDICATIONS Administration of tadalafil to patients using any form of organic nitrate is contraindicated. Tadalafil was shown to potentiate the hypotensive effect of nitrates (4.1). History of known serious hypersensitivity reaction to Tadalafil or ADCIRCA (4.2). Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3). WARNINGS AND PRECAUTIONS Patients should not use tadalafil if sex is inadvisable due to cardiovascular status (5.1). Use of tadalafil with alpha-blockers, antihypertensives or sub Przeczytaj cały dokument